Therapeutic Asset Ratings
6,371 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Ipilimumab
Recurrent Non-Hodgkin Lymphoma
OHSU Knight Cancer Institute
P2
BB
(68)
Obinutuzumab
MALT Lymphoma
University of Washington
P2
BB
(68)
Pembrolizumab
Fallopian Tube Carcinoma
Roswell Park Cancer Institute
P2
BB
(68)
Pembrolizumab
Primary Mediastinal Large B-Cell Lymphoma
Seda S. Tolu
P2
BB
(68)
Relatlimab
Neoplasm
Bristol-Myers Squibb
P2
BB
(68)
Pembrolizumab
Uveal Melanoma
BioInvent International AB
P2/3
BB
(68)
Atezolizumab
Hepatocellular Carcinoma
Icahn School of Medicine at Mount Sinai
P4
BB
(67)
Atezolizumab
Non-Small Cell Lung Carcinoma
National Cancer Institute (NCI)
P4
BB
(67)
Blinatumomab
B-Cell Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
P4
BB
(67)
Cetuximab
Colorectal Cancer
Fudan University
P4
BB
(67)
DARATUMUMAB
Plasma Cell Myeloma
Janssen Research & Development, LLC
P4
BB
(67)
Durvalumab
Durvalumab
Chang Gung Memorial Hospital
P4
BB
(67)
Durvalumab
Non-Small Cell Lung Carcinoma
University of Chicago
P4
BB
(67)
Evolocumab
Acute Stroke
The Affiliated Hospital of Xuzhou Medical University
P4
BB
(67)
Galcanezumab
Vestibular Migraine
Stanford University
P4
BB
(67)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Breast Neoplasm
Merck Sharp & Dohme LLC
P4
BB
(67)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
P4
BB
(67)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Multiple Sclerosis
Rennes University Hospital
P4
BB
(67)
Ipilimumab
Renal Cell Carcinoma
SWOG Cancer Research Network
P4
BB
(67)
Nivolumab
Non-small Cell Lung Cancer
University of Chicago
P4
BB
(67)
Pembrolizumab
Renal Cell Carcinoma
City of Hope Medical Center
P4
BB
(67)
TRASTUZUMAB
Breast Cancer
SWOG Cancer Research Network
P4
BB
(67)
Blinatumomab
Adult Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
P3
BB
(67)
Blinatumomab
Childhood Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
P3
BB
(67)
Blinatumomab
Childhood Leukemia, Acute Lymphoblastic
Institute of Hematology & Blood Diseases Hospital, China
P3
BB
(67)
Showing 176 to 200 of 6,371 assets
Previous
Page 8 of 255
Next